Indications
Management of hypertension.
Pharmacology
Bisoprolol Fumarate and Hydrochlorothiazide have been used individually and in combination for the treatment of hypertension. The antihypertensive effects of these agents are additive; Hydrochlorothiazide 6.25 mg significantly increases the antihypertensive effect of Bisoprolol Fumarate. The incidence of hypokalemia with the Bisoprolol Fumarate and Hydrochlorothiazide 6.25 mg combination is significantly lower than with Hydrochlorothiazide 25 mg. Bisoprolol Fumarate is a β1-selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing or intrinsic sympathomimetic activities in its therapeutic dose range. Hydrochlorothiazide is a benzothiadiazine diuretic. Thiazides affect renal tubular mechanisms of electrolyte reabsorption and increase excretion of sodium and chloride in approximately equivalent amounts.
Dosage & Administration
Adults:Â The effective starting dose is one 2.5-mg/6.25 mg tab once daily. If the antihypertensive effect of this dosage is not sufficient, the dose may be increased to one 5-mg/6.25 mg tab once daily and if response is still not sufficient, to two 5-mg/6.25 mg tab once daily.
Elderly:Â Elderly patients should be started on a low dose with close monitoring.
Dose adjustment is not necessary in patients with mild to moderate hepatic or renal impairment (creatinine clearance >30 mL/min).
Interaction
This combination drug may potentiate the action of other antihypertensive agents used concomitantly. BetacorTM HZ should not be combined with other beta-blocking agents. Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of Bisoprolol Fumarate may produce excessive reduction of sympathetic activity.
Reviews
There are no reviews yet.